Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Real-world Reduction in Oral Corticosteroid Utilization Following Efgartigimod Initiation in Patients Living with Generalized Myasthenia Gravis
Autoimmune Neurology
S38 - Autoimmune Neurology: Peripheral Autoimmunity, Paraneoplastic Disease, Checkpoint Inhibitors, and Neurosarcoidosis (3:42 PM-3:54 PM)
002

Reducing or tapering OCS, a commonly used treatment in gMG, can alleviate the risk of many adverse events related to long-term OCS usage.

To evaluate real-world utilization of oral corticosteroids (OCS) among patients with generalized myasthenia gravis (gMG) over the first 6 months post-efgartigimod treatment initiation.
In this retrospective cohort study, patients with gMG using OCS who initiated efgartigimod treatment were identified from a US medical and pharmacy claims database (based on information licensed from IQVIA: Longitudinal Access and Adjudication Data [LAAD] for the period April 2016−April 2023, reflecting estimates of real-world activity [all rights reserved]). Average daily dose (ADD) of OCS was analyzed: (1) during the 3-month period immediately prior to efgartigimod initiation, (2) at 3-months post-efgartigimod initiation, and (3) at 6-months post-efgartigimod initiation. The proportion of patients whose ADD changed ≥5 mg between pre- and post-efgartigimod initiation and distribution of ADD at each timepoint were evaluated.
Among 576 patients with gMG who initiated efgartigimod between January 2022-September 2022, and continued efgartigimod treatment for ≥6 months, 231 (40%) were using OCS at baseline (pre-efgartigimod) and were included in the study. At baseline, 17 (7.4%), 109 (47.1%), 105 (45.5%) of patients had OCS AAD of 0-5mg, 5-20mg, and >20mg, respectively. At 3-months and 6-months post-efgartigimod, 82 (35%) and 99 (43%) patients experienced ≥5mg reduction in ADD, respectively. The proportion of patients with ADD of 0-5mg increased more than 3-fold (7% at baseline vs. 26% 6-months post-efgartigimod) and the proportion of patients with ADD of >20mg reduced by 35% (45% at baseline vs. 29% 6-months post-efgartigimod) following efgartigimod initiation.
While additional data is required to assess longer-term patterns, early insights into OCS utilization post-efgartigimod initiation in patients with gMG indicate that a substantial proportion experienced reduction in OCS usage over the first 6 months post-efgartigimod initiation. 
Authors/Disclosures
Neelam Goyal (Stanford University)
PRESENTER
Dr. Goyal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Goyal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Goyal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Janssen. Dr. Goyal has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Goyal has received research support from Argenx.
Cynthia Qi (argenx) Ms. Qi has received personal compensation for serving as an employee of argenx.
No disclosure on file
Deborah Gelinas (ARGENX) Dr. Gelinas has received personal compensation for serving as an employee of argenx. Dr. Gelinas has stock in argenx.
Matt Jefferson Matt Jefferson has received personal compensation for serving as an employee of argenx. Matt Jefferson has stock in argenx.
No disclosure on file
No disclosure on file
No disclosure on file
Glenn Phillips Dr. Phillips has received personal compensation for serving as an employee of argenx. Dr. Phillips has stock in argenx.